top of page

Veterans Groups Demand Congress Pass Bill On VA Medical Marijuana Research Before Session Ends

  • Writer: Bob Marley
    Bob Marley
  • Dec 9, 2022
  • 3 min read

A coalition of more than 20 veterans service organizations (VSOs) sent a letter to congressional leaders on Thursday to urge the passage of a marijuana and veterans research bill before the end of the current Congress.

The groups—which include Disabled American Veterans (DAV), Iraq and Afghanistan Veterans of America (IAVA) and AMVETS—specifically want to see lawmakers take up the VA Medicinal Cannabis Research Act, which would require the U.S. Department of Veterans Affairs (VA) to conduct clinical trials into the therapeutic potential of cannabis for military veterans.

“For decades, many veterans have called for medicinal cannabis as an option for treating the unseen wounds of war and other injuries sustained through service,” the letter says. “Veterans and caregivers have consistently communicated their anecdotal experiences regarding how cannabis offers effective treatment in tackling some of the most pressing health concerns they face upon returning from war.”

Tell your member of Congress you support researching Cannabis as a solution for veterans to help heal the wounds of war and they must pass the VA Medicinal Cannabis Research Act now! Take action here👇https://t.co/JWxaEdJiGf#CannabisForVetspic.twitter.com/jkHestjAdd

— IAVA (@iava) December 9, 2022


“We remain committed to the VA’s goal of conducting research into the efficacy of medicinal cannabis as a treatment for veterans with chronic pain, PTSD, and Traumatic Brain Injuries,” it continues. “However, as a Schedule I drug under the [Food and Drug Administration], research into the efficacy of cannabis has been stagnant, cumbersome, and convoluted with red tape. Federal research into cannabis faces many bureaucratic hurdles that hinder researchers.”

On the House side, the veterans cannabis research bill is being sponsored by Reps. Lou Correa (D-CA) and Peter Meijer (R-MI). The Senate version is being led by Sens. Jon Tester (D-MT) and Dan Sullivan (R-AK). The legislation cleared a House committee last year, despite the protests of VA officials who’ve argued that it’s unduly prescriptive.

Earlier versions of the measure moved through committee in 2020 and 2018 as well, but they’ve yet to become enacted into law.

“We call on Congress to pass the VA Medicinal Cannabis Research Act to evaluate the efficacy of cannabis in treating the unseen wounds of war for all veterans,” the VSOs said in the letter to House and Senate leadership.

For decades, IAVA, @AMVETSHQ, @DAVHQ, other leading VSOs & veterans have called for medicinal cannabis as an option for treating the wounds of war sustained through service to the nation. It's time for Congress to allow for the research. Read more 👇https://t.co/XWMr5UcCMt

— IAVA (@iava) December 9, 2022


VA’s more recent opposition to the proposal has come as a disappointment to advocates who had hoped the department under President Joe Biden would ultimately embrace the modest reform.

Hopes were raised even higher after the bill sponsor, Correa, informed a separate House panel last year that he’d had a conversation with VA Secretary Denis McDonough about the issue of marijuana and veterans.

More recently, a large-scale defense spending bill that was released following bicameral negotiations this week excludes separate language from a previously House-passed version that would have authorized VA doctors to recommend medical cannabis to veterans living in legal states.

A joint explanatory statement for the National Defense Authorization Act (NDAA) did direct the Department of Defense to examine the potential of “plant-based therapies” like cannabis and certain psychedelics for service members, however.

A VA official said in September that the department is monitoring research into the therapeutic potential of psychedelics “very, very closely,” but that treatment involving the substances is not yet part of the “standard of care” for military veterans.

While Correa may be better known for his cannabis reform advocacy, he also recently formed a first-of-its-kind congressional caucus dedicated to psychedelics therapy alongside Rep. Jack Bergman (R-MI).

Meanwhile, Biden did sign a broader marijuana research bill last week that’s meant to streamline the process for researchers to obtain and study cannabis.

Read the letter from VSOs on passing the veterans and cannabis research bill below: 

Connecticut’s First Adult-Use Marijuana Sales Will Start Next Month, Officials Announce

Comments


Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page